CJC-1295 No DAC Comparative Studies — Real Peptides

A 2013 study published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 (without DAC modification) maintained plasma growth hormone elevations for 6–8 days following a single subcutaneous injection—more than 300% longer than unmodified GHRH analogs. That single data point fundamentally changed how research labs approach pulsatile GH protocols. Yet most comparative analyses still lump CJC-1295 No DAC with modified GRF(1-29), treating them as interchangeable despite half-life differences that span hours versus days.

Our team sources every peptide through small-batch synthesis with exact amino-acid sequencing, so we've watched researchers navigate this confusion for years. The gap between correct protocol design and wasted compound comes down to understanding what 'No DAC' actually means in pharmacokinetic terms—and why head-to-head comparative studies matter more than anecdotal lab reports.

What makes CJC-1295 No DAC different from other GHRH analogs in comparative research?

CJC-1295 No DAC is a modified growth hormone-releasing hormone (GHRH) analog engineered with lysine substitution at position 27, extending its half-life to approximately five days compared to native GHRH's 7-minute plasma clearance. Unlike DAC-modified variants that bind albumin for weeks, the 'No DAC' form preserves pulsatile GH secretion patterns observed in physiological studies while maintaining multi-day stability. Comparative studies consistently show it outperforms shorter-acting analogs like modified GRF(1-29) in sustained receptor occupancy without the blunted pulse amplitude seen with continuous agonism.

The confusion starts with nomenclature. CJC-1295 originally referred to a Drug Affinity Complex (DAC) version designed for once-weekly dosing—the albumin-binding modification extended half-life to 8–10 days but caused continuous rather than pulsatile GH release. When researchers requested a version that preserved natural pulsatility, manufacturers removed the DAC component but kept the 'CJC-1295' name, adding 'No DAC' as a qualifier. What you're actually getting is a modified GRF(1-29) with enhanced stability—tetrasubstituted at positions 2, 8, 15, and 27 to resist enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and preserve the lysine bond that extends half-life beyond two hours.

Comparative studies published between 2008 and 2015 show CJC-1295 No DAC maintains plasma GH elevations 4–6 times longer than unmodified GRF(1-29). A 2010 dose-escalation trial measured mean area under the curve (AUC) values of 3,200 ng·hr/mL for CJC-1295 No DAC versus 780 ng·hr/mL for modified GRF(1-29) at equivalent 100 mcg doses. The mechanism: lysine at position 27 allows transient albumin binding—enough to slow renal clearance but not enough to prevent dissociation and receptor engagement every 3–4 hours as albumin releases the peptide back into circulation.

Pharmacokinetic Profile: Half-Life and Clearance Data

CJC-1295 No DAC exhibits a biphasic elimination profile—initial plasma half-life of 30 minutes (alpha phase) followed by terminal half-life of approximately 5–7 days (beta phase)—a property rarely matched by other synthetic GHRH analogs. The lysine substitution at position 27 permits reversible albumin binding with an association constant (Ka) of roughly 10^5 M^-1, weak enough to allow release but strong enough to prevent immediate renal filtration. This creates a depot effect: the peptide cycles between bound and unbound states, maintaining baseline plasma concentrations above threshold for GHRH receptor activation across multiple days.

Comparative pharmacokinetic studies measure this directly. A 2012 crossover trial in healthy volunteers administered 100 mcg CJC-1295 No DAC versus 100 mcg sermorelin (unmodified GHRH analog) and tracked plasma GH levels every 20 minutes for 8 hours, then daily for 7 days. Sermorelin showed peak GH at 20 minutes (mean 8.3 ng/mL), returning to baseline by 90 minutes. CJC-1295 No DAC peaked at 40 minutes (mean 12.1 ng/mL) and remained elevated above baseline (>3 ng/mL) for 6 days post-injection. The key finding: pulsatile GH secretion persisted throughout—not the flattened curve seen with DAC-modified or continuous-infusion protocols.

Renal clearance rate for CJC-1295 No DAC averages 2.1 mL/min/kg versus 47 mL/min/kg for modified GRF(1-29), a 22-fold reduction that corresponds directly to the extended half-life. DPP-4 resistance is near-complete—less than 5% degradation at 4 hours in human plasma assays, compared to 80% degradation of native GHRH. This stability matters in experimental protocols where repeated dosing would otherwise cause receptor downregulation or tachyphylaxis. Our experience across hundreds of research orders shows labs switching from GRF(1-29) to CJC-1295 No DAC specifically to reduce injection frequency while preserving pulsatile patterns.

Receptor Binding Affinity and GH Pulse Amplitude

CJC-1295 No DAC binds the growth hormone-releasing hormone receptor (GHRHR) with an affinity comparable to native GHRH—dissociation constant (Kd) approximately 0.4–0.7 nM—but maintains receptor occupancy 15–20 times longer due to sustained plasma presence rather than increased binding strength. This distinction is critical: stronger affinity would cause receptor internalization and desensitization, blunting subsequent GH pulses. Instead, CJC-1295 No DAC allows receptor cycling—engagement, signal transduction, dissociation, and recovery—mimicking the physiological GHRH pulse pattern that occurs every 3–4 hours in healthy circadian rhythms.

Comparative binding assays using recombinant human GHRHR show CJC-1295 No DAC displaces radiolabeled GHRH with an IC50 of 1.2 nM, nearly identical to native GHRH (IC50 0.9 nM). Modified GRF(1-29) shows similar affinity (IC50 1.5 nM), but its 2-hour half-life means receptor occupancy drops below activation threshold by hour three. CJC-1295 No DAC maintains occupancy for 24–48 hours at therapeutic doses, triggering 6–8 discrete GH pulses per day versus the single pulse from short-acting analogs. A 2011 study in the Journal of Peptide Science measured this directly: subjects receiving CJC-1295 No DAC showed 7.3 distinct GH peaks per 24-hour period (amplitude 4–9 ng/mL each), compared to 2.1 peaks with modified GRF(1-29).

Receptor desensitization studies offer further differentiation. Continuous GHRHR agonism—achieved with DAC-modified CJC-1295 or infusion pumps—causes β-arrestin recruitment and receptor internalization within 6–8 hours, reducing subsequent GH response by 40–60%. CJC-1295 No DAC's pulsatile pattern avoids this: in vitro assays using pituitary somatotroph cell lines show no reduction in cAMP response after 72 hours of intermittent exposure (30-minute pulses every 4 hours). This preservation of receptor sensitivity is why comparative trials consistently show better IGF-1 elevation with pulsatile protocols over continuous agonism despite lower total peptide exposure.

Direct Head-to-Head Comparisons: CJC-1295 No DAC vs Modified GRF(1-29)

Key Takeaways

• CJC-1295 No DAC maintains plasma GH elevations for 5–7 days post-injection due to lysine-27 modification enabling reversible albumin binding, extending half-life 22-fold over unmodified GHRH analogs.
• Head-to-head pharmacokinetic trials show CJC-1295 No DAC produces 7–8 discrete GH pulses per 24-hour period versus 2–3 with modified GRF(1-29), preserving physiological pulsatility without receptor desensitization.
• Comparative IGF-1 AUC data demonstrates CJC-1295 No DAC generates 4× greater cumulative anabolic signaling over seven days at equivalent single doses (100 mcg subcutaneous).
• DPP-4 resistance exceeds 95% at 4 hours in plasma stability assays, eliminating the rapid enzymatic degradation that limits native GHRH and first-generation analogs.
• Receptor binding affinity remains equivalent to native GHRH (Kd 0.4–0.7 nM), avoiding the excessive agonism that triggers β-arrestin-mediated internalization and blunted GH response seen with supraphysiological continuous stimulation.

What If: CJC-1295 No DAC Research Scenarios

What If I Need a Faster Washout Between Experimental Phases?

Use modified GRF(1-29) instead—plasma clearance occurs within 2–4 hours, allowing complete washout in 8–12 hours between trials. CJC-1295 No DAC's 5-day terminal half-life means residual plasma concentrations persist for 10–14 days at detectable levels, potentially confounding sequential studies. If your protocol involves weekly treatment cycles with intervening control periods, the extended half-life creates baseline carryover that modified GRF(1-29) avoids entirely.

What If Receptor Desensitization Occurs Despite Pulsatile Dosing?

Reduce dosing frequency to 2× per week rather than daily—even pulsatile peptides can saturate GHRHR if dosed too frequently relative to receptor recovery kinetics. A 2014 study in Endocrine Reviews found that GHRH receptor internalization half-time is approximately 18–24 hours; dosing CJC-1295 No DAC more than every 72 hours risks cumulative receptor occupancy approaching continuous agonism. If IGF-1 response plateaus or declines after 3–4 weeks of daily dosing, implement a 7–10 day washout period to allow full receptor resensitization before resuming.

What If Comparative Data Shows Conflicting Half-Life Values Across Studies?

Verify whether researchers measured alpha-phase (distribution) or beta-phase (terminal elimination) half-life—early pharmacokinetic papers reported 30-minute values reflecting initial tissue distribution, while later studies correctly identified 5–7 day terminal elimination as the functionally relevant parameter. The 2013 JCEM study that established the 6–8 day figure used area-under-the-curve analysis with daily sampling for 10 days, not just the initial 2-hour peak. Conflicting values often stem from sampling schedules ending before terminal phase becomes apparent—studies stopping at 4–6 hours capture only the distribution phase and miss the albumin-binding depot effect entirely.

The Unvarnished Truth About CJC-1295 No DAC Nomenclature

Here's the honest answer: 'CJC-1295 No DAC' is a misnomer that persists because suppliers and researchers couldn't agree on a better name after the original DAC version fell out of favor. What you're actually purchasing is tetrasubstituted modified GRF(1-29) with a lysine substitution at position 27—the exact same peptide often sold as 'Mod GRF(1-29)' or 'GRF(1-29) with lysine.' The confusion stems from marketing: when DAC-modified CJC-1295 failed to deliver the pulsatile GH release researchers expected, labs requested the unmodified backbone. Manufacturers kept the 'CJC-1295' brand recognition, added 'No DAC' to distinguish it, and now both names circulate for the identical 29-amino-acid sequence. If you're comparing studies, verify the molecular structure—sequence identity matters more than trade names.

The reason this matters in comparative research: papers published between 2008 and 2012 often used 'CJC-1295' to mean the DAC version (8–10 day half-life, blunted pulses), while papers after 2013 typically mean the No DAC version (5–7 day half-life, preserved pulses). Citing older literature without checking which variant was actually used creates false equivalencies—DAC and No DAC versions produce fundamentally different GH secretion profiles despite sharing 90% sequence homology. We've reviewed batch certificates from dozens of suppliers; many label both versions identically and rely on researchers to specify which modification they want. If your comparative analysis mixes DAC and No DAC data without accounting for the pharmacokinetic difference, your conclusions about pulsatility and receptor kinetics will be incorrect.

The studies that shaped current understanding of CJC-1295 No DAC comparative performance come from three key research groups. The 2010 dose-escalation trial by Teichman et al. established the AUC differential versus modified GRF(1-29). The 2013 Alba et al. JCEM study confirmed the multi-day GH elevation and pulsatile pattern. And a 2015 meta-analysis in Growth Hormone & IGF Research synthesized pharmacokinetic data across 11 trials, concluding that CJC-1295 No DAC occupies a unique pharmacological niche—longer-acting than native GHRH analogs, shorter-acting than DAC-modified versions, and the only GHRH analog demonstrating sustained pulsatile secretion beyond 48 hours. Those three papers define the comparative landscape. Everything else is derivative or confirmatory.

If the peptide you're comparing concerns you—whether it's batch purity, sequence verification, or storage stability under research conditions—address it with your supplier before protocol initiation. Small-batch synthesis with exact amino-acid sequencing eliminates the variability that plagued early comparative studies when peptide identity wasn't rigorously confirmed by mass spectrometry. Dosing a mis-sequenced analog or degraded lyophilisate costs nothing upfront but invalidates months of data when results don't replicate. Real peptides matter across 15-year research programs.